LEADER 02503nam 2200589Ia 450 001 9910783330903321 005 20230617011620.0 010 $a0-309-18143-7 010 $a1-282-08338-4 010 $a9786612083389 010 $a0-309-55012-2 035 $a(CKB)1000000000030479 035 $a(EBL)3377982 035 $a(SSID)ssj0000237582 035 $a(PQKBManifestationID)11188329 035 $a(PQKBTitleCode)TC0000237582 035 $a(PQKBWorkID)10191597 035 $a(PQKB)11472571 035 $a(MiAaPQ)EBC3377982 035 $a(Au-PeEL)EBL3377982 035 $a(CaPaEBR)ebr10087007 035 $a(CaONFJC)MIL208338 035 $a(OCoLC)923274892 035 $a(EXLCZ)991000000000030479 100 $a20050630d2005 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aReview of the HIVNET 012 perinatal HIV prevention study$b[electronic resource] /$fCommittee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies 210 $aWashington, D.C. $cNational Academies Press$dc2005 215 $a1 online resource (149 p.) 300 $aDescription based upon print version of record. 311 $a0-309-09651-0 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Foreword""; ""Contents""; ""Executive Summary""; ""1 Introduction""; ""2 Overview of HIVNET 012""; ""3 Study Design, Treatment Assignment, and Adherence to Study Regimens""; ""4 Efficacy and Safety""; ""5 Review of Ethical Issues""; ""6 Response to the Charge to the Committee""; ""Appendixes""; ""Appendix A Agendas of Information-Gathering Meetings""; ""Appendix B Comparisons to Other Perinatal HIV Prevention Studies Using NVP and ZDV""; ""Appendix C Committee Biographies"" 606 $aHIV infections$xPrevention 606 $aHIV infections$xTransmission 606 $aPerinatology 615 0$aHIV infections$xPrevention. 615 0$aHIV infections$xTransmission. 615 0$aPerinatology. 676 $a618.3 712 02$aInstitute of Medicine (U.S.).$bCommittee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910783330903321 996 $aReview of the HIVNET 012 perinatal HIV prevention study$93709364 997 $aUNINA